Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 6, 2014, Pages 684-691

  Suárez Calvet, Marc ^a,b   Dols Icardo, Oriol ^a,b   Lladó, Albert ^c   Sánchez Valle, Raquel ^c   Hernández, Isabel ^d   Amer, Guillermo ^e   Antón Aguirre, Sofía ^a,b   Alcolea, Daniel ^a,b   Fortea, Juan ^a,b   Ferrer, Isidre ^b,f   Van Der Zee, Julie ^g,h   Dillen, Lubina ^g,h   Van Broeckhoven, Christine ^g,h   Molinuevo, José Luís ^c   Blesa, Rafael ^a,b   Clarimón, Jordi ^a,b   Lleó, Alberto ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d Institut Catala de Neurociencies Aplicades   (Spain)

^e HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^h UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRANULIN; TAR DNA BINDING PROTEIN;

ADULT; AGED; ARTICLE; C9ORF72 GENE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA STRUCTURE; FEMALE; FRONTOTEMPORAL DEMENTIA; GENE; GENE MUTATION; GRN GENE; HETEROZYGOTE; HEXANUCLEOTIDE REPEAT EXPANSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; TDP 43 PROTEINOPATHY;

ALS; CSF; DEMENTIA; FRONTAL LOBE; GENETICS;

AGED; AGED, 80 AND OVER; BLOTTING, SOUTHERN; BRAIN; CASE-CONTROL STUDIES; DNA REPEAT EXPANSION; DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MUTATION; PHOSPHORYLATION; PROTEIN PRECURSORS; PROTEINS;

EID: 84899713203     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-305972     Document Type: Article

References (40)

1. Kumar-Singh S, Van Broeckhoven C. Frontotemporal lobar degeneration: current concepts in the light of recent advances. Brain Pathol 2007;17:104-14.
2. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-54.
3. Van Langenhove T, Van der Zee J, Van Broeckhoven C, et al. The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. Ann Med 2012;44:817-28.
4. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010;119:1-4.
5. Stevens M, Van Duijn CM, Kamphorst W, et al. Familial aggregation in frontotemporal dementia. Neurology 1998;50:1541-5. (Pubitemid 28283216)
6. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442:916-9. (Pubitemid 44285946)
7. Cruts M, Gijselinck I, Van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006;442:920-4. (Pubitemid 44285947)
8. Dumanchin C, Camuzat A, Campion D, et al. Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. Hum Mol Genet 1998;7:1825-9. (Pubitemid 28464159)
9. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245-56.
10. Gijselinck I, Van Langenhove T, Van der Zee J, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 2012;11:54-65.
11. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257-68.
12. Van der Zee J, Gijselinck I, Dillen L, et al. A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat 2013;34:363-73.
13. Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006;351:602-11. (Pubitemid 44708852)
14. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-3. (Pubitemid 44547757)
15. Benajiba L, Le Ber I, Camuzat A, et al. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol 2009;65:470-3.
16. Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008;319:1668-72. (Pubitemid 351432505)
17. Hu WT, Trojanowski JQ, Shaw LM. Biomarkers in frontotemporal lobar degenerations-progress and challenges. Prog Neurobiol 2011;95:636-48.
18. Foulds P, McAuley E, Gibbons L, et al. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. Acta Neuropathol 2008;116:141-6.
19. Foulds PG, Davidson Y, Mishra M, et al. Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. Acta Neuropathol 2009;118:647-58.
20. Kasai T, Tokuda T, Ishigami N, et al. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol 2009;117:55-62.
21. Steinacker P, Hendrich C, Sperfeld AD, et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol 2008;65:1481-7.
22. Fortea J, Lladó A, Clarimón J, et al. PICOGEN: five years experience with a genetic counselling program for dementia. Neurologia 2011;26:143-9.
23. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-77.
24. Gorno-Tempini ML, Hillis A, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006-14.
25. Antonell A, Gil S, Sánchez-Valle R, et al . Serum progranulin levels in patients with frontotemporal lobar degeneration and Alzheimer's disease: detection of GRN mutations in a Spanish cohort. J Alzheimers Dis 2012;31:581-91.
26. Dols-Icardo O, Suárez-Calvet M, Hernández I, et al. Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia. Neurobiol Aging 2012;33:1851.e17-19.
27. Costa S, Suárez-Calvet M, Antón S, et al. Comparison of 2 diagnostic criteria for the behavioral variant of frontotemporal dementia. Am J Alzheimers Dis Other Demen 2013;28:469-76.
28. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385-93.
29. Fukumoto H, Rosene DL, Moss MB, et al. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 2004;164:719-25. (Pubitemid 38364685)
30. Dols-Icardo O, García-Redondo A, Rojas-García R, et al. Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Hum Mol Genet Published Online First: 20 September 2013. doi:10.1093/hmg/ddt460
31. Josephs KA, Hodges JR, Snowden JS, et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 2011;122:137-53.
32. Finch N, Baker M, Crook R, et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 2009;132:583-91.
33. Ghidoni R, Benussi L, Glionna M, et al. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 2008;71:1235-9.
34. Sleegers K, Brouwers N, Van Damme P, et al. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol 2009;65:603-9.
35. Blennow K, Hampel H, Weiner M, et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-44.
36. Bian H, Van Swieten JC, Leight S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 2008;70:1827-35. (Pubitemid 351653951)
37. Bibl M, Gallus M, Welge V, et al. Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia. J Neural Transm 2012;119:805-13.
38. Kapaki E, Paraskevas GP, Papageorgiou SG, et al. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 2008;22:47-53. (Pubitemid 351651397)
39. Buratti E, Baralle FE. The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol 2010;7:420-9.
40. Neumann M, Kwong LK, Lee EB, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 2009;117:137-49.